Assessment of changes in brain metabolites in Indian patients with type-2 diabetes mellitus using proton magnetic resonance spectroscopy by Sanjeev Sinha et al.
Sinha et al. BMC Research Notes 2014, 7:41
http://www.biomedcentral.com/1756-0500/7/41RESEARCH ARTICLE Open AccessAssessment of changes in brain metabolites in
Indian patients with type-2 diabetes mellitus
using proton magnetic resonance spectroscopy
Sanjeev Sinha1*, Meera Ekka1, Uma Sharma2, Raghunandan P1, R M Pandey3 and N R Jagannathan2Abstract
Background: The brain is a target for diabetic end-organ damage, though the pathophysiology of diabetic
encephalopathy is still not well understood. The aim of the present study was to investigate the effect of diabetes on the
metabolic profile of brain of patients having diabetes in comparison to healthy controls, using in-vivo magnetic
resonance spectroscopy to get an insight into the pathophysiology of cerebral damages caused due to diabetes.
Methods: Single voxel proton magnetic resonance spectroscopy (1H-MRS) was performed at 1.5 T on right frontal,
right parieto-temporal and right parieto-occipital white matter regions of the brain of 10 patients having type-2
diabetes along with 7 healthy controls. Absolute concentration of N-acetylaspartate (NAA), choline (cho), myo-inositol
(mI), glutamate (Glu) and glutamine (Gln), creatine (Cr) and glucose were determined using the LC-Model and
compared between the two groups.
Results: The concentration of N-acetylaspartate was significantly lower in the right frontal [4.35 ±0.69 vs. 5.23 ±0.74;
p = 0.03] and right parieto-occipital region [5.44 ±0.52 vs.6.08 ±0.25; p = 0.02] of the brain of diabetics as compared to
the control group. The concentrations of glutamate and glutamine were found to be significantly higher in the right
frontal region of the brain [7.98 ±2.57 vs. 5.32 ±1.43; P = 0.01] in diabetics. Glucose levels were found significantly
elevated in all the three regions of the brain in diabetics as compared to the control group. However, no significant
changes in levels of choline, myo-inositol and creatine were observed in the three regions of the brain examined
among the two groups.
Conclusions: 1H-MRS analysis indicates that type-2 diabetes mellitus may cause subtle changes in the metabolic profile
of the brain. Decreased concentrations of NAA might be indicative of decreased neuronal viability in diabetics
while elevated concentrations of Gln and Glu might be related to the fluid imbalance resulting from disruption of
glucose homeostasis.
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Type-2 diabetes mellitus (DM) is one of the common
metabolic diseases that affects approximately 61.3 million
people in India alone. It has been projected to increase
further to 101.2 million by 2030 [1]. DM is associated with
cognitive deficits and an increased risk of dementia, par-
ticularly in the elderly [2]. A recent study reported that
patients with type-2 DM show impairments in several* Correspondence: drsanjeevsinha2002@yahoo.com
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reproduction in any medium, provided the orcognitive domains, mostly in the area of verbal memory
and processing speed [3]. Moreover, some recent evi-
dences have shown that the brain is a target for diabetic
end-organ damage, though the pathophysiology of dia-
betic encephalopathy is still not well understood. Both
vascular and metabolic disturbances have been suggested
to impair the integrity of the brain in diabetes [4]. Diffuse
diabetic angiopathy, ischemic lesions and diffuse degen-
erative abnormalities have been described in patients with
type-1 DM; however, in type-2 DM cognitive impairments
may be relatively more pronounced that may be due
to chronic hyperglycaemia, vascular disease, repeatedtd. This is an open access article distributed under the terms of the Creative
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sulin on the brain as implicated in various studies [5]. A
recent report documented the possible brain abnormal-
ities caused among obese adolescents with type-2 DM;
which may result from a combination of subtle vascular
changes, glucose and lipid metabolic abnormalities, and
subtle differences in adiposity in the absence of clinic-
ally significant vascular diseases [6].
Various imaging modalities including MRI (Magnetic
Resonance Imaging), MRS (Magnetic Resonance Spectros-
copy), CT scan, PET (Positron Emission Tomography),
SPECT (Single-Photon Emission Computed Tomography)
and cerebral blood flow imaging have been used to study
the pathology of the brain inflicted by diabetes mellitus
[7]. Proton magnetic resonance spectroscopy (1H-MRS)
is a sensitive, non-invasive technique that provides me-
tabolic information on the status of viability of neurons
and on the membrane metabolism of the brain [8,9]. The
brain metabolites, generally observed in 1H-MRS, are: N-
acetylaspartate (NAA), choline (Cho), creatine (Cr), myo-
inositol (mI), glutamate (Glu) and glutamine (Gln). Several
researchers have studied the metabolic changes in the
brain due to various clinical disorders affecting the central
nervous system, including tumours, infarction and ische-
mia, multiple sclerosis, Alzheimer’s disease, and epilepsy
[10,11]. It has also been used to assess metabolic changes
in the brain of patients with obstructive sleep apnea
(OSA) and COPD [12,13].
In the present study, a systematic investigation was
carried out to understand the effect of diabetes on three
regions of the brain of patients with type-2 DM using
1H-MRS. This study focused on the determination of ab-
solute concentrations of NAA, Cho, Cr, Glx, mI and glu-
cose in frontal, parieto-temporal and parieto-occipital
white matter areas of the brain. This study was based on
the hypothesis that cerebral metabolism is affected in
type-2 diabetics due to chronic hyperglycaemia/hypoxia
affecting the levels of cerebral metabolites. It was expected
that patients with type-2 DM have lower levels of NAA,
with concurrent higher levels of mI, cho and glucose.
Methods
This prospective observational pilot study was conducted
at All India Institute of Medical Sciences, New Delhi- a
tertiary level referral centre. The protocol of the study was
reviewed and approved by the ethics committee of All
India Institute of Medical Sciences, New Delhi. All par-
ticipants were informed about the study and their writ-
ten consents were obtained.
Selection of subjects
This study was conducted on ten patients with type 2
DM and seven healthy subjects who volunteered to par-
ticipate in the study. The patients were recruited fromthe outpatient clinic of the Department of Medicine based
on the following criteria: (1) age >30 years at the time of
diagnosis of diabetes, (2) systolic blood pressure <130 mm
Hg and diastolic blood pressure <80 mm Hg, (3) no pro-
teinuria (urinary albumin excretion rate <20 μg/min, (4)
no history of cerebrovascular and cardiovascular symp-
toms or disorders. The healthy subjects and patients were
matched for age, gender, height and weight.
Complete history, physical examinations and labora-
tory tests were performed in all subjects to exclude the
effect of diseases other than diabetes. All subjects had
normal blood counts, serum creatinine levels, electro-
lyte concentrations and electrocardiograms. The sub-
jects were not on antihypertensive, anticoagulants, or
lipid-lowering drugs except for two cases. The patients
were using oral hypoglycaemic agents for DM.
Biochemical investigations
Venous blood samples were drawn after a 10–12 hour
overnight fast for the estimation of blood glucose, total
cholesterol (TC), serum triglyceride (TG), and high-density
lipoprotein cholesterol (HDL-C). The total cholesterol, TG
and HDL-C were measured using commercially available
kits (Randox Laboratory, San Francisco, CA, USA) on a
semi-automated analyser (Micro Semi-Autoanalyser 2000,
C. L. Micromed, Italy). Low-density lipoprotein cholesterol
(LDL-C) was estimated using Friedewald’s formula: LDL −
C=TC − (HDL −C+TG/5) [14]. Non-HDL cholesterol
was calculated by deducting the value of HDL −C from
total cholesterol. Normal value for lipid was defined
by the standard criteria used by National Cholesterol
Education Program [15]. Diabetes mellitus was diag-
nosed according to the protocol of American Diabetes
Association [16]. Glycosylated haemoglobin (HbA1C)
assay was performed on HPLC (BioRad, Richmond,
CA, USA).
1H-MRS of the brain
1H-MRS (proton magnetic resonance spectroscopy) ana-
lysis was performed on a total of 17 subjects (10 - dia-
betic and 7 - control) using volume-localized 1H-MRS at
1.5 Tesla MRI/MRS scanner (MAGNETOM, Siemens,
Germany) using a circularly polarized (CP) coil. Prior to
1H-MRS analysis, multi-slice T1-weighted images of the
coronal and sagittal planes of the whole brain were ac-
quired using a standard spin-echo pulse sequence (TE =
15 ms; TR = 520 ms; 3–5 mm slice thickness; 256 × 256
matrix). T2-weighted axial images were acquired using
the following parameters: TE = 90 ms; TR = 250 ms; 3–
5 mm slice thickness; 256 ×2 56 matrix). These images
were used to identify the region of interest for perform-
ing the volume-localized 1H-MRS. The spectra were re-
corded using PRESS pulse sequence with the following
parameters: TR = 2000 ms; TE = 30 ms; NS = 128. Care
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by carrying out global and voxel shim. The line-width
after voxel shim ranged from 5–9 Hz depending on the
voxel size and the region studied. The spectra were ac-
quired from three different regions of the brain viz. from
right frontal, right parieto-temporal and right occipital
white matter. However, spectra from all the three regions
of the brain could not be recorded for all the subjects due
to long acquisition time and patients’ non-cooperation.
The spectra from right frontal white matter were acquired
for all the ten patients and seven controls. While spectra
from right parieto-temporal white matter were acquired
for nine patients and five controls; that from the right oc-
cipital white matter were only acquired in eight diabetics
and four controls.
Statistical analysis
After confirming the approximate normality, normally
distributed data were expressed as arithmetic means and
standard deviation. The two groups were compared
using Student’s t-test for continuous variables and x2
tests for categorical variables. Statistical analysis was per-
formed using statistical software package ‘STATA version




Baseline blood chemistry reports were available only for
eleven subjects as mentioned earlier. None of the healthy
control subjects were smokers or alcoholics and have any
history of hypertension, hyperlipidaemia or cerebrovas-
cular disease. There was no differences among the indi-
viduals of the two groups with reference to age, sex,Table 1 Baseline characteristic of study subjects
Parameter Group1: diabetes (n = 1
Age (yr) 39 ±5.19
BMI (kg/m2) 25.91 ±5.24
Serum cholesterol (mg/dl) 191 (125–239)
Serum LDL cholesterol (mg/dl) 123 (55–150)
Triglyceride (TG)(mg/dl) 151 (110–272)
Serum HDL cholesterol (mg/dl) 44.5(43–46)
Systolic blood pressure (mm Hg) 131.75 ±20.7
Diastolic blood pressure (mm Hg) 77.75 ±2.06
Age at onset of DM (yr) 37.75 ±2.06
Duration of DM (yr) 3.5 ±1.2
Fasting blood glucose (mg/dl) 195.5 (113–256)
HbAIC (%) 7.25 (6.8–8.9)
CRP (Median, range) 4.8 (4.5–5.5)
Serum Insulin 6.95 (5.8–12)ethnicity, education, blood pressure level or BMI. As ex-
pected, with reference to the controls, the type-2 dia-
betic patients had significantly higher levels of fasting
blood glucose, C-reactive protein and HbA1C (p < 0.05).
The groups did not show any significant differences
with reference to the total cholesterol, LDL cholesterol,
triglycerides and HDL cholesterol. The patients were di-
agnosed for type-2 DM 3.5 (±1.2) years earlier.
Proton magnetic resonance spectroscopy
The absolute concentrations of NAA, Cho, Cr, Glc and
Glx, summarised in Tables 1 and 2, were calculated
using LC model. The absolute concentration of NAA
was found to be significantly lower in diabetic group as
compared to control group in right frontal [4.35 ±0.69
vs. 5.23 ±0.74; p = 0.03] and right parieto-occipital region
[5.44 ±0.52 vs.6.08 ±0.25; P = 0.0]. On the other hand,
the level of Glx (Glu + Gln) was found significantly in-
creased [7.98 ±2.57 vs.5.32 ±1.43; p = 0.01] in the right
frontal area in diabetic group; however, no significant
differences were observed in the other two areas of the
brain examined (p > 0.05). Interestingly, Glc was found
to be significantly higher in the three regions of the
brain in diabetic group as compared to control group
(p < 0.01). However; the absolute concentrations of Cho,
mI and Cr did not show any significant difference between
the two groups in the three regions of the brain under
investigation (p > 0.05) Figure 1.
Discussion
In this study, the localized 1H-MRS was used to measure
the absolute concentrations of brain metabolites in white
matter areas of right frontal, right parieto-temporal and




































NAA 4.53 ±0.69 5.23 ±0.74 0.03 5.53 ±0.42 5.83 ±0.76 0.17 5.44 ±0.52 6.08 ±0.25 0.02
Cr + PCr 3.23 ±0.26 3.43 ±0.50 0.15 3.84 ±0.31 3.61 ±0.42 0.11 3.72 ±0.26 3.86 ±0.22 0.19
GPC + PC 0.94 ±0.16 0.86 ±0.14 0.14 1.03 ±0.30 1.09 ±0.13 0.24 0.97 ±0.13 0.90 ±0.19 0.25
Glu + Gln 7.98 ±2.57 5.32 ±1.43 0.01 6.74 ±1.30 6.72 ±1.94 0.48 7.49 ±1.64 6.44 ±1.68 0.15
Glc 1.57 ±0.98 0.43 ±0.21 0.004 2.33 ±0.86 0.69 ±0.88 0.005 1.78 ±0.67 0.79 ±0.45 0.01
mI 2.93 ±0.60 2.65 ±0.43 0.15 3.06 ±0.62 2.66 ±0.36 0.09 3.03 ±0.38 2.81 ±0.25 0.16
Figure 1 1H-MRS (proton magnetic resonance spectrum) from right parieto-occipital region of a control (A) and a patient (B).
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that the variations in brain metabolites were not uniform
across different regions of the brain studied. NAA was
found significantly decreased in the right frontal and
right parieto-occipital regions, while Glx showed a sig-
nificant increase in frontal area in the diabetic group as
compared to the control. The level of glucose was in-
creased in all the three regions of brain in the diabetic
group as compared to the control (p < 0.05). There were
no measurable changes in the levels of Cho, Cr and mI
in any of the three regions of the brain. Further, the data
indicated that the frontal white matter and parieto-
occipital lobes were the most affected in diabetics. Simi-
lar results were reported by Ajilore et al. and Sahin et al
[4,17]. These findings are consistent with recent studies
reporting that patients with type-2 DM execute persist-
ently worse in all cognitive functions, especially tasks
that involve intellectual functioning, verbal memory and
psychomotor performances [7]. In addition, some studies
demonstrated the involvement of white matter tract in
the frontal lobe, temporal lobe, cingulate, occipital lobe
and cerebral peduncle which explains the cognitive slow
down in these patients [6].
Our study indicated that NAA levels were significantly
decreased in diabetics as compared to the control group.
NAA is an amino acid that is exclusively synthesised and
localised in neurons. It acts as a major osmolyte and also
serves as a marker of neuronal viability [18]. The pri-
mary role of NAA is neuronal-glial cell specific signal-
ling for the optimal functions of the central nervous
system [19]. The decline in brain NAA reflects axonal or
neuronal dysfunction, or loss in neuronal density similar
to that observed in stroke, hypoxia, neoplasm, epilepsy,
multiple sclerosis and dementia [20]. Muranyi et al. re-
ported that, in an animal model, hyperglycaemia causes
mitochondrial swelling consequently initiating hypoxic
cell death cascade in brain [21]. In our study, decreased
levels of NAA observed in diabetic patients may reflect
neuronal loss possibly due to chronic hyperglycaemia or
ischemia. Sahin et al. studied a group of 25 patients with
type-2 DM that included 13 patients with impaired glu-
cose tolerance test and 14 healthy controls. They found
that Cho/Cr ratios were increased in frontal cortex in pa-
tients with IGT where as mI/Cr ratios were increased in
frontal cortex, and Cho/Cr ratios decreased in parietal
cortex in patients with type-2 DM as compared to the
controls. They also found that HbA1C level was inversely
correlated with NAA/Cr and Cho/Cr ratios in the frontal
cortex and with Cho/Cr ratio in parietal white matter [17].
However, contrary to these studies, Tiehuis et al. studied
72 patients with type-2 DM and 40 control subjects using
1H-MRS and reported no differences in NAA/Cr, Cho/Cr
or NAA/Cho ratios between patients with type-2 DM and
controls; and neither cognitive performance in patientswith type-2 DM was correlated with any of these brain
metabolites nor were the clinical variables [22]. Some au-
thors have used 1H-MRS to evaluate brain metabolites in
type-2 diabetic patients with other co-morbidity such as
depression and hypothyroidism and have reported variable
results. Ajilore et al. found, in a study comprising patients
with type-2 DM with major depression (n = 24), DM alone
(n = 24) and healthy controls (n = 21), significant increase
in absolute concentrations of mI in frontal white matter in
DM alone and DM with major depression patients as
compared to healthy controls [4]. However, the study of
ten patients with type-1 DM reported by Makimattila
et al. showed increased levels of Cho and mI in white mat-
ter in comparison with ten healthy controls, with inverse
correlation of glycaemic exposure with NAA and Cho in
white matter and with Cho in grey matter [19].
The present results showed no significant differences
in the concentration of Cr and mI between patients
with DM and controls. Similar results were obtained by
Makimattila et al. [19]. Few studies have reported signifi-
cant increase in mI in frontal white matter in patients with
DM with or without depression as compared to healthy
subjects [4,23]. Myo-Inositol, a naturally occurring sugar
and membrane constituent, reflects proliferation or activa-
tion of glia. It also serves as a cell messenger, astrocyte
marker in diabetes, as well as a possible marker for intra-
cellular osmotic integrity. Decreased levels of myo-inositol
have been reported in hyperosmolar state, stroke, gliosis,
tumours, lymphoma and some low grade lymphoma
[24,25]. Similarly in the present study, no significant dif-
ferences in the concentrations of Cho were observed be-
tween the two groups. Choline containing compounds
are indicator of cell density and cell wall turnover. They
also reflect metabolism of myelin and other phospho-
lipids of cell membrane. The levels of choline contain-
ing compounds elevate under certain conditions such as
in chronic ischemia, tumours, especially malignant ones,
and in certain demyelinating diseases [25-27].
The present study further indicates significantly higher
levels of Glu and Gln (Glx) in right frontal regions of
the brain of patients with DM. Glu and Gln (Glx) are
putative osmolytes and their presence may indicate fluid
imbalance resulting from regular disruption of glucose
homeostasis. Our results also showed significantly higher
levels of glucose in all the three regions of the brain ex-
amined in DM group as compared to the control. The
level of glucose may also increase during osmotic distur-
bances related to hyperglycaemia in DM patients. This
fact is supported by the earlier studies of Makimatilla
et al. and Brand et al. [19,28]. Similarly, a previous study
by de Graaf et al. has shown that glucose content of the
brain is linearly related to the plasma glucose level [29].
However, a recent study by Kim et al. in patients with
well controlled type-1 DM showed that brain glucose
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fer between healthy subjects and patients with uncompli-
cated type-1 DM under hypoglycaemic conditions [30].
However, besides the results presented herein, this study
has some limitations which need to be addressed such as
small sample size. In addition, some blood tests were not
done in few patients due to discontinued follow up. In
conclusion, it is clear that type-2 DM causes subtle cere-
bral metabolic changes. Decreased NAA might be indica-
tive of decreased neuronal viability in diabetics as a result
of chronic hypoxia and hyperglycaemia. Increased glutam-
ate and glutamine levels may be due to the effect of hyp-
oxia and hypoglycaemia. However, these conclusions need
to be confirmed by further studies with large sample size.
Conclusions
1H-MRS analysis indicates that type-2 diabetes mellitus
may cause subtle changes in the metabolic profile of the
brain. In conclusion, it is clear that type-2 DM causes sub-
tle cerebral metabolic changes. Decreased NAA might be
indicative of decreased neuronal viability in diabetics as a
result of chronic hypoxia and hyperglycaemia. Increased
glutamate and glutamine levels may be due to the effect of
hypoxia and hypoglycaemia. However, these conclusions
need to be confirmed by further studies with large sample
size.
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